There is a widespread assumption in clinical research that more process equals better science. More monitoring, more forms, more approvals — a study with more oversight is assumed to be a more rigorous study. For high-risk interventional research, this intuition has a basis. For low-risk observational and nutritional studies, it is often simply wrong — and expensive.
Where over-engineering comes from
Over-engineering is rarely deliberate. It accumulates through a combination of institutional inertia, professional risk-aversion, and the application of processes designed for high-risk contexts to studies that don't warrant them.
CRO templates and standard operating procedures are often developed for the most complex study types and then applied uniformly. Sponsors accustomed to high-governance frameworks expect them. Research ethics committees apply similar scrutiny regardless of risk level. Site staff with trial backgrounds follow trial procedures because that is what they know.
The result is a low-risk dietary study run with the governance infrastructure of a complex interventional trial — multiple monitoring visits, extensive source data verification, weekly oversight calls, elaborate amendment procedures — none of which adds proportionate value to the data quality or participant safety.
The real costs
The costs of over-engineering are both direct and indirect.
Direct costs are the most visible: monitoring activities that are not risk-justified, data management processes calibrated for far more complex data, regulatory submission work for procedures that didn't require it, and staff time spent on compliance activities rather than scientific work.
Indirect costs are less visible but often larger. Studies that are over-engineered are harder to set up, slower to recruit, and more burdensome for sites. Institutions that might otherwise participate are deterred by the overhead. Investigators who would contribute to a lightweight study decline when they see the administrative commitment required. The result is a smaller, less representative sample — and science that is technically compliant but less useful.
There is also an opportunity cost: budgets consumed by unnecessary process are not available for the activities that would actually improve the evidence. A better dietary assessment tool, a larger sample, a longer follow-up period, or a more diverse recruitment strategy would typically do more for scientific quality than an additional monitoring visit.
A simple illustration: a low-risk observational nutrition study governed with a full interventional-trial monitoring schedule might spend a large share of its site budget on scheduled monitoring visits that find nothing requiring action, because the data being verified — food diary entries, questionnaire responses — carries little of the risk that on-site source data verification exists to catch. The same budget, redirected to central statistical monitoring plus a second reminder call for participants at risk of dropping out, would typically do more for the study's actual data quality than the visits it replaced.
What proportionate governance looks like
Proportionate governance means matching oversight to risk — not applying maximum oversight as a default. For low-risk observational and nutritional studies, this typically means:
- Risk-based monitoring: Central review of key data points rather than extensive on-site source data verification. Triggered monitoring for signals rather than scheduled visits by default.
- Streamlined documentation: Core required documents without the full site file appropriate to a complex interventional study. Essential records that are genuinely informative, not comprehensive archives that satisfy a checklist.
- Fit-for-purpose data systems: Data capture tools calibrated to the study's actual data complexity, not enterprise systems deployed for a simple questionnaire study.
- Clear governance roles: Oversight proportionate to the study's risk profile, with the right level of committee involvement — not maximum involvement because it is standard practice.
The ICH's updated GCP guideline (ICH E6(R3)) explicitly supports this direction, introducing a proportionate approach to oversight as a core principle rather than a supplementary consideration.
The evidence that proportionate oversight works
This isn't just a design philosophy — there's now a concrete, published example of it working in practice. The MHRA ran a "Route B" pilot for substantial modifications to low-risk approved clinical trials between October 2025 and March 2026, built on exactly this logic: let lower-risk changes move through a lighter review process than higher-risk ones, freeing up expert assessor time for the trials that actually need it.
The pilot's own stated aim was to cut review time without compromising participant safety — and the results bore that out well enough that Route B has since become a mandated part of the Clinical Trials Regulations rather than staying an optional pilot. The underlying principle scales down cleanly to non-CTIMP governance too: matching the level of scrutiny to the level of risk isn't a shortcut, it's what frees up capacity for the studies where scrutiny actually changes the outcome.
How to push back
Sponsors and study teams who recognise over-engineering can push back — but it requires confidence and early engagement.
The most effective moment is at the protocol development stage, before templates are applied and processes are locked in. The right questions to ask explicitly: what is the risk profile of this study, and what does that actually require? What monitoring approach is justified by the risk? What documentation is genuinely necessary?
Working with a CRO that understands proportionate governance — and has genuine experience designing low-risk studies without over-engineering them — makes this conversation much easier. The goal is a study that is rigorous where rigour matters and efficient where it doesn't. Those two things are not in tension. Getting the balance right is what good study design looks like.